Sonnet BioTherapeutics Holdings, Inc.: Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest ... | Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq®) The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg in combination... ► Artikel lesen |
Sonnet BioTherapeutics Holdings, Inc.: Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. | PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted... ► Artikel lesen |
Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas | SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy... ► Artikel lesen |
Cava Group To Replace Altair Engineering In The S&P MidCap 400 | WASHINGTON (dpa-AFX) - S&P Dow Jones Indices, a division of S&P Global (SPGI), announced that Cava Group Inc. (CAVA) will replace Altair Engineering Inc. (ALTR) in the S&P MidCap 400 effective... ► Artikel lesen |
S&P Dow Jones Indices: Cava Group Set to Join S&P MidCap 400 and Angi to Join S&P SmallCap 600 | NEW YORK, March 26, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, and S&P SmallCap 600:
Cava Group Inc.... ► Artikel lesen |
Restaurant-Kette: Aktienrücksetzer nutzen? JPMorgan sieht bei CAVA eine fette Kaufchance! | © Foto: Arno Burgi/dpa-Zentralbild/dpaAnleger sollten laut JPMorgan die jüngste Schwächephase von der US-Restaurantkette Cava zum Einstieg nutzen.Analyst John Ivankoe hat die Aktie der mediterranen... ► Artikel lesen |